FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312683487> ?p ?o ?g. }

• W4312683487 abstract "Abstract Background Clinical presentation with STEMI is considered as a highly prothrombotic condition often associated with recurrent ischemic events. The role of aspirin as part of antiplatelet regimens in STEMI patients needs to be clarified especially in the context of new potent P2Y12 inhibitors Aim To assess the benefit and risk of 23-month ticagrelor monotherapy after one month of DAPT against the conventional 12-month DAPT with aspirin and ticagrelor followed by aspirin monotherapy among STEMI patients in the GLOBAL LEADERS trial. Methods We did a post hoc analysis of STEMI patients in the GLOBAL LEADERS trial (2092 patients). We compared the experimental ticagrelor monotherapy group (1062 patients) with the standard 12-month DAPT group (1030 patients) in rates of GLOBAL LEADERS predefined primary (composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction (MI) and secondary end points (BARC 3 or 5 bleeding). NACE (Net Adverse Clinical Events) and POCE (Patient- Oriented Composite End points). We also compared GLOBAL LEADERS predefined end points in STEMI, UA, NSTEMI and CCS in both treatment arms. Results At two years, there were no significant differences in rates of GLOBAL LEADERS primary end points in patients who had or did not have STEMI. BARC bleeding in either treatment group didn't vary significantly among STEMI, NSTEMI and UA. Nevertheless, the experimental strategy had led to significant increase in BARC bleeding in CCS compared with STEMI at 1 and 2 years. There were similar rates of NACE and POCE in both the experimental and reference treatment groups at 1 and 2 years post PCI. Conclusions and relevance The incidence of GLOBAL LEADRER defined end points has not been impacted by STEMI presentation. Our findings suggest that an earlier cessation of DAPT at 1 month post primary PCI, with continuation of a potent P2Y12 antagonist monotherapy, could be safe and avoids additional bleeding risk in the STEMI setting. Given the post-hoc nature of the analysis, our findings should not necessitate changes in recommendations for practice by professional associations and regulatory agencies. However, all reported findings should rather be considered only as hypothesis-generating and need be replicated in dedicated large-scale randomized trials to further assess the role of Aspirin free antithrombotic strategies post PCI in STEMI. Funding Acknowledgement Type of funding sources: None." @default.
• W4312683487 created "2023-01-05" @default.
• W4312683487 creator A5006259187 @default.
• W4312683487 creator A5029562118 @default.
• W4312683487 creator A5037601700 @default.
• W4312683487 creator A5038409870 @default.
• W4312683487 creator A5041449436 @default.
• W4312683487 creator A5042853338 @default.
• W4312683487 creator A5051004343 @default.
• W4312683487 creator A5051191205 @default.
• W4312683487 creator A5056462138 @default.
• W4312683487 creator A5060718390 @default.
• W4312683487 creator A5061524536 @default.
• W4312683487 creator A5072851353 @default.
• W4312683487 creator A5089985000 @default.
• W4312683487 creator A5090690137 @default.
• W4312683487 date "2021-10-01" @default.
• W4312683487 modified "2023-10-02" @default.
• W4312683487 title "Efficacy and safety of early aspirin withdrawal and continuation of ticagrelor monotherapy post PCI for STEMI. A post hoc analysis of the randomized global leaders trial" @default.
• W4312683487 doi "https://doi.org/10.1093/eurheartj/ehab724.2998" @default.
• W4312683487 hasPublicationYear "2021" @default.
• W4312683487 type Work @default.
• W4312683487 citedByCount "1" @default.
• W4312683487 countsByYear W43126834872022 @default.
• W4312683487 crossrefType "journal-article" @default.
• W4312683487 hasAuthorship W4312683487A5006259187 @default.
• W4312683487 hasAuthorship W4312683487A5029562118 @default.
• W4312683487 hasAuthorship W4312683487A5037601700 @default.
• W4312683487 hasAuthorship W4312683487A5038409870 @default.
• W4312683487 hasAuthorship W4312683487A5041449436 @default.
• W4312683487 hasAuthorship W4312683487A5042853338 @default.
• W4312683487 hasAuthorship W4312683487A5051004343 @default.
• W4312683487 hasAuthorship W4312683487A5051191205 @default.
• W4312683487 hasAuthorship W4312683487A5056462138 @default.
• W4312683487 hasAuthorship W4312683487A5060718390 @default.
• W4312683487 hasAuthorship W4312683487A5061524536 @default.
• W4312683487 hasAuthorship W4312683487A5072851353 @default.
• W4312683487 hasAuthorship W4312683487A5089985000 @default.
• W4312683487 hasAuthorship W4312683487A5090690137 @default.
• W4312683487 hasBestOaLocation W43126834871 @default.
• W4312683487 hasConcept C126322002 @default.
• W4312683487 hasConcept C151730666 @default.
• W4312683487 hasConcept C164705383 @default.
• W4312683487 hasConcept C168563851 @default.
• W4312683487 hasConcept C2777628954 @default.
• W4312683487 hasConcept C2779343474 @default.
• W4312683487 hasConcept C2780400711 @default.
• W4312683487 hasConcept C2780890252 @default.
• W4312683487 hasConcept C45393284 @default.
• W4312683487 hasConcept C49059817 @default.
• W4312683487 hasConcept C500558357 @default.
• W4312683487 hasConcept C67761136 @default.
• W4312683487 hasConcept C71924100 @default.
• W4312683487 hasConcept C86803240 @default.
• W4312683487 hasConceptScore W4312683487C126322002 @default.
• W4312683487 hasConceptScore W4312683487C151730666 @default.
• W4312683487 hasConceptScore W4312683487C164705383 @default.
• W4312683487 hasConceptScore W4312683487C168563851 @default.
• W4312683487 hasConceptScore W4312683487C2777628954 @default.
• W4312683487 hasConceptScore W4312683487C2779343474 @default.
• W4312683487 hasConceptScore W4312683487C2780400711 @default.
• W4312683487 hasConceptScore W4312683487C2780890252 @default.
• W4312683487 hasConceptScore W4312683487C45393284 @default.
• W4312683487 hasConceptScore W4312683487C49059817 @default.
• W4312683487 hasConceptScore W4312683487C500558357 @default.
• W4312683487 hasConceptScore W4312683487C67761136 @default.
• W4312683487 hasConceptScore W4312683487C71924100 @default.
• W4312683487 hasConceptScore W4312683487C86803240 @default.
• W4312683487 hasIssue "Supplement_1" @default.
• W4312683487 hasLocation W43126834871 @default.
• W4312683487 hasOpenAccess W4312683487 @default.
• W4312683487 hasPrimaryLocation W43126834871 @default.
• W4312683487 hasRelatedWork W2355614377 @default.
• W4312683487 hasRelatedWork W2375232986 @default.
• W4312683487 hasRelatedWork W2375584960 @default.
• W4312683487 hasRelatedWork W2380518343 @default.
• W4312683487 hasRelatedWork W2967518830 @default.
• W4312683487 hasRelatedWork W2981952708 @default.
• W4312683487 hasRelatedWork W3029448752 @default.
• W4312683487 hasRelatedWork W3035565530 @default.
• W4312683487 hasRelatedWork W3125666540 @default.
• W4312683487 hasRelatedWork W4313339810 @default.
• W4312683487 hasVolume "42" @default.
• W4312683487 isParatext "false" @default.
• W4312683487 isRetracted "false" @default.
• W4312683487 workType "article" @default.